Cytokinetics CYTK
Callos Andrew (Officer) plans to sell 59,570 CYTK shares, about $3.8M
- Form
- 144
- Filed
- Importance
- Routine
- Accession
- 0001950047-26-000082
- Approximate sale date: Jan 2, 2026
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
- Shares acquired by: Exercise of Stock Options; Performance Stock Units
- 10b5-1 plan adopted: Sep 5, 2025
All of Callos Andrew's insider filings, holdings and planned sales
Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):
- Sold 913 shares at $62.09 on Jan 2, 2026 · Form 4
- Sold 885 shares at $63.16 on Jan 2, 2026 · Form 4
- Sold 15,000 shares at $60.28 on Jan 5, 2026 · Form 4
- Sold 886 shares at $62.1 on Feb 2, 2026 · Form 4
- Sold 15,000 shares at $61.93 on Feb 5, 2026 · Form 4
- Sold 886 shares at $61.62 on Mar 2, 2026 · Form 4
- Sold 15,000 shares at $61.87 on Mar 5, 2026 · Form 4
- Sold 11,000 shares at $61.88 on Mar 5, 2026 · Form 4
Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- TG Therapeutics TGTX public float $2.5B, Jun 30, 2025
- Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
- Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
- Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
- Carisma Therapeutics CARM
